Recent meta-analysis pooling of 16 randomized control trials regarding patients with heart failure in general indicated that SGLT2 inhibition was associated with modest but statistically significant reductions in systolic BP (1.68 mmHg) but not diastolic BP (1.06 mmHg) (20). This evidence concerns the gene SLC5A2 and heart failure.